Advancing the Future
of Precision Oncology.
Vivos Inc. is a biotech company developing advanced technologies for human and veterinary oncology applications.
Vivos Inc. Precision Radionuclide Therapy™
Products
IsoPet® is our division dedicated to treating cancers in animals using our patented Precision Radionuclide Therapy™ (PRnT). Our innovative approach in the treatment of cancerous tumors focuses on delivering targeted radiation directly to cancerous tumors in a single treatment while minimizing damage to surrounding healthy tissues.
Deliver your active pharmaceutical with quick-dissolving, biodegradable thermogel consisting of poly(lactide-co-glycolide)-graft-poly(ethylene glycol). Initially developed at Pacific Northwest Laboratories and further refined by a collaboration between Vivos, Inc. and Akina, Inc.
RadioGel® is our division dedicated to treating cancer in humans using our patented Precision Radionuclide Therapy™ (PRnT). RadioGel® is currently not approved for human use or commercial distribution in the United States. It is being studied under an FDA-approved Investigational Device Exemption (IDE) for clinical trials only.
Welcome to a New Way
of Treating Cancer
Vivos Inc. is a medical device company with its patented Precision Radionuclide Therapy™. Vivos Inc. (OTCQB: RDGL) was incorporated in 2018 with the goal of developing an innovative cancer treatment. Our proprietary and revolutionary Precision Radionuclide Therapy™ (PRnT) is the future of radionuclide cancer treatment with the insertion of our radionuclide device directly into the tumor tissue.
